Menu Search
Equities

OXB

OXB:LSE

OXB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)417.50
  • Today's Change5.00 / 1.21%
  • Shares traded21.76k
  • 1 Year change+109.38%
  • Beta1.5924
Data delayed at least 20 minutes, as of Nov 11 2024 10:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year OXB's revenues fell -36.04% from 139.99m to 89.54m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 39.16m to a larger loss of 157.49m.
Gross margin36.74%
Net profit margin-172.59%
Operating margin-170.29%
Return on assets-51.98%
Return on equity-119.16%
Return on investment-66.85%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at OXB fell by 37.57m. However, Cash Flow from Investing totalled 2.81m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 28.52m for operations while cash used for financing totalled 12.70m.
Cash flow per share-1.41
Price/Cash flow per share--
Book value per share0.6292
Tangible book value per share0.3444
More ▼

Balance sheet in GBPView more

OXB has a Debt to Total Capital ratio of 60.77%, a lower figure than the previous year's 63.61%.
Current ratio2.35
Quick ratio2.07
Total debt/total equity1.66
Total debt/total capital0.6077
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.